Abstract
Background: The two replicate, randomised, placebo-controlled, 52-week INPULSIS® trials assessed the efficacy and safety of nintedanib 150 mg bid in patients with IPF. Patients with FVC ≥50% predicted were included. The primary endpoint, the annual rate of FVC decline, was significantly reduced in the nintedanib group compared with placebo in both trials, consistent with slowing of disease progression. Key secondary endpoints were time to first acute exacerbation and change from baseline in SGRQ total score, both over 52 weeks.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.